natgillin/translations-raw huggingface dataset:
The glove according to claim 5, wherein said piece of information is a colour scale. 
Rukavica u skladu s patentnim zahtjevom 5, naznačena time što je navedena informacija skala boja.
Novick, D., Engelmann, H., Wallach, D. and Rubinstein. 
Novick, D., Engelmann, H., Wallach, D. i Rubinstein.
A body as claimed in claim 2, wherein the compressive strength is approximately 10 Newton, or approximately 30 Newton. 
Tijelo sukladno patentnom zahtjevu 2, pri čemu je tlačna čvrstina približno 10 Newtona, ili približno 30 Newtona.
vaporising the alcohol in the slurry as the steam is injected into the slurry; and separating the alcohol vapour from the remaining slurry. 
isparavanje alkohola u kaši kako se para ubrizgava u kašu; i odvajanje alkoholne pare od preostale kaše.
Preferably, the ion exchange resin used for the capture step is a strong anion exchanger matrix, such as e.g. Q Sepharose Fast Flow. 
Poželjno, nosač za izmjenu iona koji se koristi za lovljenje proteina je matriks s jakim anionskim izmjenjivačem poput Q Sepharose Fast Flow.
The method of waterless processing of textile materials using supercritical fluid according to claim 7, wherein during the procedure of sedimentation of the functional material, the supercritical carbon dioxide with the dissolved functional material in the high-pressure cauldron is led back to an entry port of the functional material can through a control valve, a flow meter and a high-pressure cycling pump, thereby repeatedly performing sedimentation of the functional material until the functional material is fully absorbed by the textile material. 
Metoda bezvodne obrade tekstilnih materijala korištenjem superkritičnog fluida kao što je navedeno u zahtjevu 1, dalje obuhvaćajući korak: dodavanja funkcionalnog materijala u posudu za bojanje koja sadrži materijal za bojanje, provođenje superkritičnog ugljikovog dioksida u posudu za bojanje kako bi otopio materijal za bojanje i funkcionalan materijal; i provođenje superkritičnog ugljikovog dioksida s otopljenim materijalom za bojanje i funkcionalnim materijalom kroz visokotlačni kotao u kojem se nalazi tekstilni materijal, time time izvodeći sedimentiranje materijala za bojanje i funkcionalnog materijala na tekstilni materijal
The co-formulation composition of claim 13 further comprising sodium chloride at a concentration of 50-200 mM and wherein the concentration of lodoxamide is 0.5-1 mg/ml and the concentration of the peptide is 5-20 mg/ml. 
Suformulacija pripravka u skladu s patentnim zahtjevom 13, naznačena time što dodatno sadrži natrijev klorid u koncentraciji od 50-200 mM, te gdje je koncentracija lodoksamida 0,5-1 mg/ml, a koncentracija peptida je 5-20 mg/ml.
The method of item 22, wherein the infectious disease caused by human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), human cytomegalovirus (HCMV), hepatitis C, papillomavirus, Plasmodium, Kaposi's sarcoma associated herpesvirus, Varicella zoster virus, Ebola virus, Mycobacterium tuberculosis, Chikungunya virus, dengue virus, monkeypox virus, herpes simplex 1, herpes simplex 2, Epstein-Barr virus (EBV), poliovirus, influenza virus, or Clostridium tetani. 
Rekombinantni vektor RhCMY ili HCMY ili pripravak u skladu s patentnim zahtjevom 13, naznačen time što zaraznu bolest uzrokuje virus humane imunodeficijencije (HIV), virus majmunske imunodeficijencije (SIV), ljudski citomegalovirus (HCMV), hepatitis C, papilomavirus, plazmodij, herpesvirus povezan s Kaposijevim sarkomom, virus varicela-zoster, virus ebole, Mycobacterium tuberculosis, virus Chikungunya, virus denge, virus majmunskih boginja, herpes simpleks 1, herpes simpleks 2, Epstein-Barrov virus (EBV), poliovirus, virus influence ili Clostridium tetani.
The system as claimed in claim 1 wherein the first and second electrodes are orthogonal to the exit orifice and wherein the first electrode has a planar tip and the second electrode has a pointed tip. 
Sustav prema zahtjevu 1, pri čemu su prva i druga elektroda (2b.1, 2b.2) postavljene ortogonalno u odnosu na izlazni otvor (2c) te pri čemu prva elektroda (2b.1) ima ravan, a druga (2b.2) šiljasti vrh.
The method of claim 4, wherein the modification is a substitution of phenylalanine to an amino acid selected from among leucine, isoleucine, valine, alanine, glycine, methionine, serine, threonine, cysteine, tryptophan, lysine, arginine, histidine, proline, tyrosine, asparagine, glutamine, aspartic acid and glutamic acid at amino acid position 876 of the AR polypeptide, optionally wherein the modification is a substitution of phenylalanine to an amino acid selected from among glycine, alanine, valine, leucine, and isoleucine at amino acid position 876 of the AR polypeptide, optionally wherein the modification is a substitution of phenylalanine to leucine at amino acid position 876 of the AR polypeptide. 
Postupak prema patentnom zahtjevu 4, pri čemu je modifikacija supstitucija fenilalanina s aminokiselinom izabranom između leucina, izoleucina, valina, alanina, glicina, metionina, serina, treonina, cisteina, triptofana, lizina, arginina, histidina, prolina, tirozina, asparagina, glutamina, asparaginske kiseline i glutaminske kiseline na poziciji aminokiseline 876 AR polipeptida, opcionalno pri čemu je modifikacija supstitucija fenilalanina s aminokiselinom izabranom između glicina, alanina, valina, leucina i izoleucina na poziciji aminokiseline 876 AR polipeptida, opcionalno pri čemu je modifikacija supstitucija fenilalanina s leucinom na poziciji aminokiseline 876 AR polipeptida.
mixing Nalmefene hydrochloride (17-cyclopropylmethyl)-4,5-a-epoxy-6-methylenemorphinan-3,14-diol hydrochloride) and aqueous solution such as water, 
miješanje nalmefen hidroklorida (17-ciklopropilmetil)-4,5-a-epoksil-6-metilenmorfinan-3,14-diol hidroklorid) i vodene otopine kao što je sama voda,
The entire length of the article is preferably wrapped with cigarette paper 46. 
Cjela dužina artikla je poželjno umotana sa cigaret papirom 46.
The use of the compounds of the formula I as claimed in one or more of claims 1 to 4 for the manufacture of a medicament for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders. 
. Spojevi formule I u skladu s jednim ili više patentnih zahtjeva 1 do 23, namijenjeni upotrebi u liječenju i/ili sprječavanju poremećaja metabolizma masnih kiselina i poremećaja upotrebe glukoze.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
A process of preparing the crystalline form of claim 1, said process comprising the steps of dissolving 7-chloro- N, N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4 H -pyridazino[4,5- b]indole-1-acetamide in dichloromethane at a concentration of about 20 mg/ml to about 50 mg/ml to form a solution, adding the solution to hexanes to cause a precipitation of a solid, and isolating the solid. 
Postupak dobivanja kristalnog oblika u skladu s patentnim zahtjevom 1, naznačen time što se navedeni postupak sastoji u koracima otapanja 7-klor-N,N,5-trimetil-4-okso-3-fenil-3,5-dihidro-4H-piridazino[4,5-b]indol-1-acetamida u diklormetanu, u koncentraciji od otprilike 20 mg/ml do otprilike 50 mg/ml, kako bi se dobilo otopinu, dodavanja otopine u heksane kako bi došlo do taloženja krutine, te izdvajanja krutine.
about 1 to about 4 pH units below the pI of the polypeptide; 
oko 1 do oko 4 pH-jedinice ispod pI-vrijednosti monoklonskog protutijela;
The system according to claim 7, wherein the limited time period is extended by a predetermined user action such as banknote, ticket or currency input to the terminal. 
Sustav za igranje sukladno patentnom zahtjevu 6, pri čemu se ograničeni vremenski period produžava unaprijed definiranom akcijom korisnika, kao što je umetanje novčanice, kartice ili gotovine u korisnički terminal (2).
Ueq is defined as one third of the trace of the orthogonalized Uij tensor. Atom 
Uc, je definiran kao jedna trećina zapisa ortogonaliziranog U tenzora. Atom
an antibody heavy chain variable domain, or antigen binding fragment thereof, of 11. A binding compound that binds to human IL-23, comprising a light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein: 
HR P20120611 T1 PATENTNI ZAHTJEVI Antitijelo ili antigen-vežući fragment istog koji se veže za humani IL-23, naznačeno time, što sadrži: a) varijabilnu domenu lakog lanca, ili antigen-vežući fragment istog, koja sadrži CDRLI, CDRL2 i CDRL3, pri čemu:
A nitroxyl donor for use in a method of treating pulmonary hypertension, which method comprises administering to a mammal in need thereof an effective amount of the nitroxyl donor, wherein the nitroxyl donor is a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: 
OT OCH; 10. Donor nitroksila za primjenu u metodi za liječenje plućne hipertenzije, pri čemu metoda sadrži administriranje kod sisavaca kojima je potrebna efikasna količina donora nitroksila, gdje je donor nitroksila spoj formule (I):
It was further found that, surprisingly, the biological activity of the compositions according to the present invention is increased by the addition of methionine. 
Tekući pripravak prema zahtjevu 1, naznačen time da sadrži farmaceutski prihvatljiv konzervans, naročito m- krezol.
Generally speaking, dermatological compositions may be provided in several designs such as in the form of an emulsion (including a microemulsion and a liposome formulation), gel, solution, liniment, ointment, foam, spray, aerosol, microsponge, patch or powder. 
Pripravak prema zahtjevu 18, naznačen time da je pripravak u obliku emulzije, kreme, losiona, gela, melema, masti, paste ili pjene. .
Thereby, according to the invention, it is particularly preferred that the drying takes place directly after the cutting process. 
Na taj način, u skladu s ovim izumom, naročito je poželjno da se sušenje događa direktno nakon postupka rezanja.
The tyrosine hydroxylase inhibitor, the melanin promoter, the p450 3A4 promoter or the leucine aminopeptidase inhibitor for use according to claim 6, wherein the cancer is breast cancer. 
Inhibitor tirozin hidroksilaze, promotorski spoj za melanin, promotorski spoj za p450 3A4 ili inhibitor leucin aminopeptidaze za uporabu prema patentnom zahtjevu 6, naznačen time što rak predstavlja rak dojke.
A compound of the formula wherein R1 is hydrogen, R2 is hydrogen, and R3 is hydrogen; 
Spoj formule [image], naznačen time što je vodik, R2 je vodik i R3 je vodik;
The pharmaceutical composition of claim 8, wherein the GLP-1 R agonist is selected from GLP-1(7-37), GLP-1(7-36)amide, extendin-4, liraglutide, CJC-1131, albugon, albiglutide, exenatide, exenatide-LAR, oxyntomodulin, lixisenatide, geniproside, AVE-0010 (SEQ ID NO: 9), a short peptide with GLP-1 R agonistic activity and/or a small organic compound with GLP-1R agonistic activity. 
Farmaceutski pripravak za uporabu prema zahtjevu 8, naznačen time što je agonist GLP-1 R odabran od GLP-1 (7-37), GLP-1 (7-36)amida, eksendina-4, liraglutida, CJC-1131, albugona, albiglutida, eksenatida, eksenatida-LAR, oksintomodulina, liksisenatida, geniprozida, kratkog peptida s aktivnošću agonista GLP-1R i/ili malog organskog spoja s aktivnošću agonista GLP-1R.
NO:73 and a light chain variable region encoded by SEQ. ID. 
NO:73 1 varijabilno područje lakog lanca kojeg kodira SEQ. ID.
An irrelevant antibody was included as a negative control (−ve Ab). 
(Sigma P-8047). Kao negalivna kontrola uključeno je irelevanino protutijelo (vni Ab).
Accordingly, the present invention provides an immunogenic composition comprising an M72 related antigen, wherein the M72 related antigen comprises a sequence having at least 90% identity to SEQ ID No: 1, wherein the conductivity of the composition is 5 mS/cm or lower and the pH of the composition is in the range 7.0 to 9.0. 
Imunogeni pripravak koji sadrži antigen povezan s M72, naznačen time što antigen povezan s M72 sadrži slijed koji je najmanje 90% istovjetan SEQ ID No: 1, pH navedenog pripravka je u rasponu od 7,0 do 9,0, a vodljivost pripravka je 5 mS/em ili manja.
providing kernels of a barley plant according to any one of claims 6 to 9; steeping said kernels; 
(i) - pružanje zrnja ječma sukladno bilo kojem od zahtjeva 6 do 9;
Solar concentrator according to Claim 9, characterized in that the body (1) comprises at least one of the following polymers: polyacrylates and polymethyl methacrylates, polyolefins, polyvinyls, epoxy resins, polycarbonates, polyacetates, polyamides, polyurethanes, polyketones, polyesters, polycyanoacrylates, silicones, polyglycols, polyimides, fluorinated polymers, polycellulose and derivatives such as methyl cellulose, hydroxymethyl cellulose, polyoxazines, and silica-based glasses. 
Koncentrator sunčevog zračenja u skladu s patentnim zahtjevom 9, naznačen time što tijelo (1) sadrži najmanje jedan od sljedećih polimera: poliakrilata i polimetil-metakrilata, poliolefina, polivinila, epoksidnih smola, polikarbonata, poliacetata, poliamida, poliuretania, poliketona, poliestera, policijanoakrilata, silikona, poliglikola, poliimida, fluoriranih polimera, policeluloze i njezinih derivata, poput metilceluloze, hidroksimetilceluloze, polioksazina, te stakla na bazi silicijevog dioksida.
A single immunoglobulin variable domain antibody according to any one of claims 1-11 for use in a method of treating, alleviating or preventing an autoimmune disease or a graft-related disease, preferably a disease selected from the group consisting of an allograft rejection, a xenograft transplant rejection, graft versus host disease, systemic lupus erythematosis, Sjogren's syndrome, multiple sclerosis, rheumatoid arthritis, diabetes, psoriasis, scleroderma, atherosclerosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and lupus nephritis. 
Antitijelo koje sadrži jednu imunoglobulinsku varijabilnu domenu ili dvojno specifični ligand za uporabu prema zahtjevu 11, naznačeni time, što se spomenuta bolest u svezi sa kalemom bira iz grupe koja se sastoji od odbacivanja alokalmea, odbacivanja ksenokalemskog transplanta 1 bolesti kalema protiv domaćina; ili gdje se spomenuta autoimunska bolest bira iz grupe koja se sastoji od sustavnog eritemskog lupusa, multiple skleroze, reumatoidnog artritisa, dijabetesa, psorijaze, skleroderme, Sjčgren-ovog sindroma, ateroskleroze, upalne bolesti crijeva, Crohn-ove bolesti i ulcerativnog kolitisa.
The method of any one of the preceding claims, wherein the biological sample originates from a smoker individual who, at the moment of the collection of the sample, does not present a pulmonary tumor if subjected to imaging diagnostic methods, in particular the smoker individual not presenting nodules of dimensions of greater than 5mm if subjected to a spiral CT scan. 
Metoda iz bilo kojeg od prethodnih patentnih zahtjeva, naznačena time, što je biološki uzorak porijeklom od osobe koja je pušač, koja u momentu uzimanja uzorka ne prikazuje tumor pluća ako se podvrgne dijagnostičkim metodama vizualizacije, preciznije, osobe koja je pušač, koja ne prikazuje nodule dimenzija preko 5 mm ako se podvrgne spiralnom CT skeniranju.
• when RCG1 represents a -C≡CH function or an activated C≡C, RCG2 represents a -N3 group; 
* kada RCGI predstavlja -C=CH funkciju ili aktivirani C=C, RCG2 predstavlja skupinu -N;;
clarifying the cell lysate by centrifugation, 
pročišćavanje staničnog lizata centrifugiranjem,
These patents describe a key blank that includes a generally elongate shaft portion defining a key combination surface adapted to have formed thereon key cuts which define a key combination. 
Ti patenti opisuju prazan ključ koji ima obično izduženi trup ključa, ujedno i površinu za formiranje kombinacije ključa pomoću ureza koji zapravo određuju kombinaciju ključa.
Combination according to any one of claims 1 to 4 where the inflammatory disease is a respiratory disease selected from asthma or COPD, rheumatism or an auto-immune disease selected from rheumatoid arthritis, glomerulonephritis, multiple sclerosis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus or psoriasis. 
Kombinacija sukladno patentnom zahtjevu 2, naznačena time, da je bolest dišnih putova astma ili kronična opstruktivna plućna bolest (COPD). 4. Kombinacija sukladno patentnom zahtjevu 2, naznačena time, da je autoimuna bolest reumatoidni artritis, glomeruloneftitis, multipla skleroza, Crohnova bolest, ulcerozni kolitis, sistemski lupus eritematosus ili psorijaza.
Figure 11 is a section therethrough on the line XI-XI of Figure 10. 
je presjek limene metalne trake duž linije XI-XI iz slike 10, slika 12
The suspension is heated until the donepezil hydrochloride has completely dissolved in the solvent. 
Suspenzija se zagrija sve dok se donepezil hidroklorid potpuno ne rastopi u otapalu.
In particular, the valve element 5 can return from the intermediate position to the first position allowing refill of the metering chamber 6 with liquid 4 . 
Posebno, element ventila 5 može se vratiti iz međupoložaja u prvi položaj koji omogućuje ponovno punjenje odmjerne komore 6 s tekućinom 4.
In related aspects, the antibody or antigen-binding fragment of the invention binds hIL-6R with an affinity at least 2-fold higher than it binds monkey IL-6R. 
Antitijelo ili njegov fragment koji se veže na antigen prema zahtjevu 1, 2 ili 3, naznačen time, da se veže na hIL6R s afinitetom najmanje 1,5 puta većim u odnosu na afinitet vezivanja prema IL-6R majmuna.
The oral dosage form of any one of claims 1 to 10, further comprising a pharmaceutical excipient. 
Farmaceutski sastav koji sadrži efektivnu količinu jednog ili više spojeva prema bilo kojem od zahtjeva 1 do 15 i farmaceutski prihvatljiv nositelj.
With regard to the water contents, the aqueous ethanol preferably contains 20 to 99.9 vol% of ethanol, and the aqueous acetone preferably contains 20 to 99.9 vol% of acetone. 
Sastav koji sadrži piceatanol, prema zahtjevu 3, naznačen time, da vodeni etanol sadrži od 20 do 99,9 volumenskih % etanola. Sastav koji sadrži piceatanol, prema zahtjevu 3, naznačen time, da vodeni aceton sadrži od 20 do 99,9 volumenskih % acetona.
For example the hydroxy protecting group, Pg, in a compound of the Formula XI as hereinbefore described in Reaction Scheme 1 is removed to give the compound of the Formula XIII: 
Na primjer, uklanjanjem hidroksi zaštitne skupine, Pg, u spoju prikazanom Formulom XI u skladu sa ranijim opisom u Reakcijskoj Shemi 1, dobije se spoj prikazan Formulom XIII:
ii) transforming the compound of formula (III) into the corresponding nitrile derivative of formula (IV). 
(III) 1i) pretvorba spoja formule (III) u odgovarajući nitrilni derivat formule (TV).
wherein the body is sized and shaped so as to allow air that has entered the air freshener device through the first vent to become scented and flow out of the air freshener device through a second vent included in the air freshener device. 
pri čemu je tijelo dimenzionirano i oblikovano tako, da omogućava zraku koji je ušao u uređaj za osvježivanje zraka kroz ulazni otvor, da se aromatizira i struji izvan uređaja za osvježivanje zraka kroz izlazni otvor (414) koji je razmaknut od ulaznog otvora na uređaju za osvježivanje zraka i koji je uključen u gornji odsječak ili donji odsječak uređaja.
A compound of Claim 4, wherein R1 is substituted or unsubstituted tetrahydropyran or substituted or unsubstituted tetrahydropyranyloxy. 
Spoj prema Zahtjevu 4, naznačen time, da R1 je supstituirani ili nesupstituirani tetrahidropiran ili supstituirani ili nesupstituirani tetrahidropiraniloksi.
A compound having the following Formula I: or a salt thereof. 
Spoj prema Formuli I: ili njegova sol.
Furthermore, buprenorphine treatment appears to be well accepted by pregnant mothers, compared to methadone treatment, as demonstrated by compliance with therapy (Fischer et al., Addiction 2000, 95(2):239-244). 
Nadalje, čini se da je liječenje buprenorfinom dobro prihvaćeno od strane trudnih majka, u usporedbi s liječenjem metadonom, što se pokazuje pristajanjem na terapiju (Fischer et al., Addiction 2000, 95(2):239-244).
(a) at least 97% of the cells in the population express on their surfaces detectable levels of MIC A/B, 
(a) (i) najmanje 97 % stanica u populaciji na svojoj površini izražava uočljive razine MIC A/B,
Figure 1 is a plan view of a hand-held transmitter unit which forms part of the present invention, and also an end view illustrating an optional control for an anchor winch; 
Slika 1 je planarni prikaz na ručnu jedincu odašiljača koja čini dio opisanog izuma, i također pogled odostraga koji prikazuje opcionalnu kontrolu za sidreno vitlo;
a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:135 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:134; 
(b) VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 135i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 134;
A one-way valve is preferably associated with the inlet port, being fitted in such a way as to allow air into the main volume from the exterior, but not in the reverse direction. 
Respirator, kako se zahtijeva u patentnom zahtjevu 3, naznačen time, da je navedeni ulazni otvor (5) nadalje montiran s jednosmjernim ventilom (9) koji može raditi da propusti zrak u glavni volumen (16) izvana, ali ne u obratnom smjeru.
The absorber may be fastened on the inactive surfaces of the optical element with an adhesive 16 . The distance between the absorber and the reflectors 12, 13 may be larger than 0, between 0.1 to 50 mm, preferably 0.2 to 10 mm and most preferably between 0.5 and 2.5 mm. 
Informacijski sustav u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje je prigušivač osiguran na udaljenosti većoj od 0, poželjno između 0.1 do 50 mm, poželjnije između 0.2 do 10 mm, i najpoželjnije između 0.5 i 2.5 mm od reflektora (12, 13).
a nucleic acid, DNA or RNA, coding for an antibody, or for a derived compound or functional fragment of same, according to one of the claims 4 to 13 and 15; 
Izolirana nukleinska kiselina, naznačena time da rečena izolirana nukleinska kiselina, DNA ili RNA, kodira za antitijelo prema jednom od patentnih zahtjeva 5 ili 8.
The ground engaging apparatus (10) of Claim 7 wherein said hollow body has a length and a non-circular cross-section along said length. 
Sklop (16) spojnog klina prema Zahtjevu 1 gdje: navedeno šuplje tijelo posjeduje dužinu i nekružni poprečni presjek duž navedene dužine.
at least one aromatase inhibitor which is selected from letrozole or exemestane or a pharmaceutically acceptable salt thereof for use in the treatment of breast cancer. 
ili - njegovu farmaceutski prihvatljivu sol, te inhibitor aromataze koji je eksemestan ili letrozol, pri čemu on služi za uporabu u liječenju raka dojke.
A method for establishing if an asymptomatic heart failure, a chronic heart failure or an acute heart failure patient which has been already hospitalized for an asymptomatic heart failure, a chronic heart failure or an acute heart failure is susceptible to be again hospitalized for the same disease, wherein said method comprises measuring the concentration of Insulin-like Growth Factor-Binding Protein 2 (IGFBP2) in a blood, plasma or serum sample that has been obtained from said heart failure patient. 
HR P20190801 T1 PATENTNI ZAHTJEVI Postupak ustanovljavanja je li pacijent s asimptomatskom srčanom insuficijencijom, kroničnom srčanom insuficijencijom ili akutnom srčanom insuficijencijom koji je već hospitaliziran za asimptomatsku srčanu insuficijenciju, kroničnu srčanu insuficijenciju ili akutnu srčanu insuficijenciju podložan za ponovnu hospitalizaciju za istu bolest, naznačen time što se navedeni postupak sastoji u mjerenju koncentracije proteina 2 koji se veže na inzulinu sličan čimbenik rasta (IGFBP2) u uzorku krvi, plazme ili seruma dobivenom iz navedenog pacijenta sa srčanom insuficijencijom.